Blocking IL1RAP Disrupts Pancreatic Cancer's Shield — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Sylvester Comprehensive Cancer Center researchers found that blocking IL1RAP disrupted the inflammatory network that helps pancreatic tumors resist treatment, reducing immune-suppressive cells and fibrosis while boosting T cell activity in preclinical experiments.
- Jashodeep Datta, M.D. and colleagues published the findings in JCI Insight, describing IL1RAP as a shared "helper" receptor that coordinates inflammatory signals linking tumor cells, immune cells, and fibroblasts into a treatment-resistant system.
- Sylvester is launching a first-of-its-kind neoadjuvant clinical trial that will combine IL1RAP targeted therapy with chemoimmunotherapy in patients with operable pancreatic cancer before surgery.
- The trial design lets researchers compare tumor biology before and after treatment in each patient, offering direct evidence of how IL1RAP blockade changes cancer behavior in humans.
- The work is funded by an $800,000 V Foundation Translational Research Grant over four years, awarded after a national peer review process to select bench-to-bedside projects.
- The strategy comes as KRAS targeted therapy has extended survival in metastatic pancreatic cancer but remains years away from operable cases, leaving an urgent gap the IL1RAP approach is designed to fill.
Why it matters: Pancreatic cancer's treatment-resistant microenvironment has stymied chemo and immunotherapy for years, and targeting IL1RAP attacks the inflammatory signaling network that shields tumors rather than the cancer cells themselves. With KRAS targeted therapies still years away from operable patients, this $800,000 V Foundation-funded neoadjuvant trial gives surgical candidates a new strategy and lets researchers measure tumor biology before and after treatment in each patient.
Ask SkimNews
